Tools to study the function of the Ras-related, estrogen-regulated growth inhibitor in breast cancer

被引:4
作者
Hanker, Ariella B. [1 ]
Morita, Staeci [2 ]
Repasky, Gretchen A. [3 ]
Ross, Douglas T. [4 ,5 ]
Seitz, Robert S. [4 ,5 ]
Der, Channing J. [1 ,2 ,6 ]
机构
[1] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA
[3] Birmingham So Coll, Dept Biol, Birmingham, AL USA
[4] Appl Genom Inc, Huntsville, AL USA
[5] Appl Genom Inc, Burlingame, CA USA
[6] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
来源
SMALL GTPASES IN DISEASE, PT B | 2008年 / 439卷
关键词
D O I
10.1016/S0076-6879(07)00405-3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The Ras-related, estrogen-regulated growth inhibitor (Rerg) is a Ras-related small GTPase and candidate tumor suppressor. Rerg gene expression is stimulated by the estrogen receptor alpha (ER alpha), and Rerg gene expression is absent in ER-negative breast cancers. ER-negative breast cancers are highly invasive and metastastic and are typically more advanced than their ER-positive counterparts. Like Ras, Rerg binds and hydrolyzes GTP, but unlike Ras, Rerg has been shown to possess growth inhibitory activity in breast cancer cells. The precise role that Rerg loss plays in breast cancer growth and the mechanisms by which it does so are unknown. This chapter describes tools used to detect and manipulate the expression of Rerg in breast cancer cells. We validate use of an antibody to detect Rerg expression. We describe the generation of expression vectors that encode wild-type and mutants of Rerg that are altered in GDP/GTP regulation. We also describe the development of an inducible Rerg expression system and of a retrovirus- based RNA interference approach to repress Rerg expression. These toots will be invaluable in evaluating the biological function of Rerg in breast cancer.
引用
收藏
页码:53 / +
页数:21
相关论文
共 21 条
  • [11] Lim KH, 2005, CANCER CELL, V8, P381, DOI 10.1016/j.ccr.2005.10.014
  • [12] ADVANCED MAMMALIAN GENE-TRANSFER - HIGH TITER RETROVIRAL VECTORS WITH MULTIPLE-DRUG SELECTION MARKERS AND A COMPLEMENTARY HELPER-FREE PACKAGING CELL-LINE
    MORGENSTERN, JP
    LAND, H
    [J]. NUCLEIC ACIDS RESEARCH, 1990, 18 (12) : 3587 - 3596
  • [13] siRNA-directed inhibition of HIV-1 infection
    Novina, CD
    Murray, MF
    Dykxhoorn, DM
    Beresford, PJ
    Riess, J
    Lee, SK
    Collman, RG
    Lieberman, J
    Shankar, P
    Sharp, PA
    [J]. NATURE MEDICINE, 2002, 8 (07) : 681 - 686
  • [14] PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430
  • [15] A molecular signature of metastasis in primary solid tumors
    Ramaswamy, S
    Ross, KN
    Lander, ES
    Golub, TR
    [J]. NATURE GENETICS, 2003, 33 (01) : 49 - 54
  • [16] Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
    Repasky, GA
    Chenette, EJ
    Der, CJ
    [J]. TRENDS IN CELL BIOLOGY, 2004, 14 (11) : 639 - 647
  • [17] Use of conditionally active Ras fusion proteins to study epidermal growth, differentiation, and neoplasia
    Reuter, Jason A.
    Khavari, Paul A.
    [J]. REGULATORS AND EFFECTORS OF SMALL GTPASES: RAS FAMILY, 2006, 407 : 691 - 702
  • [18] Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer
    Ring, Brian Z.
    Seitz, Robert S.
    Beck, Rod
    Shasteen, William J.
    Tarr, Shannon M.
    Cheang, Maggie C. U.
    Yoder, Brian J.
    Budd, G. Thomas
    Nielsen, Torsten O.
    Hicks, David G.
    Estopinal, Noel C.
    Ross, Douglas T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3039 - 3047
  • [19] Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
    Sorlie, T
    Perou, CM
    Tibshirani, R
    Aas, T
    Geisler, S
    Johnsen, H
    Hastie, T
    Eisen, MB
    van de Rijn, M
    Jeffrey, SS
    Thorsen, T
    Quist, H
    Matese, JC
    Brown, PO
    Botstein, D
    Lonning, PE
    Borresen-Dale, AL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) : 10869 - 10874
  • [20] Tarutani M, 2003, CANCER RES, V63, P319